Lee Ferguson
Acute Care · Oxford, MSNPI 1891188660
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,074 of the $4,674 with a category attached, or 65.8%. 20 manufacturers reported payments, led by Boston Scientific at 24.3% of the total. Reporting peaked in 2023 at $1,686 and has fallen 59.2% since, to $687 in 2025.
Across 176 payments — averaging $26.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Merck$906
- Medtronic$679
- Novartis$301
- Pfizer$281
- Johnson & Johnson$248
- plus $1K from 14 others
What the payments were for
- Travel & lodging$1,60034%
- Food & beverage$3,07466%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 11 | $1,134 |
| Merck | 49 | $906 |
| Medtronic | 5 | $679 |
| Novartis | 23 | $301 |
| Pfizer | 18 | $281 |
| Johnson & Johnson | 15 | $248 |
| AstraZeneca | 11 | $226 |
| E.r. Squibb & Sons, L.L.C. | 6 | $196 |
| Alnylam Pharmaceuticals Inc. | 9 | $171 |
| Esperion Therapeutics, Inc. | 5 | $110 |
| Boehringer Ingelheim | 6 | $101 |
| Amgen | 6 | $90 |
| Abiomed | 2 | $56 |
| Amarin Pharma, Inc. | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 1 | $24 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
How this compares
$4,674 in reported general payments places this provider in the 85th percentile of 223 acute care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 280 | $268,402 |
| EliquisApixaban | 338 | $263,223 |
| Repatha SureclickEvolocumab | 101 | $109,272 |
| XareltoRivaroxaban | 77 | $84,821 |
| FarxigaDapagliflozin Propanediol | 74 | $75,987 |
| JardianceEmpagliflozin | 49 | $33,893 |
| BrilintaTicagrelor | 35 | $22,952 |
| Praluent PenAlirocumab | 18 | $14,543 |
| Ranolazine ErRanolazine | 156 | $9,761 |
| Metoprolol Succinate | 834 | $7,827 |
| Ezetimibe | 377 | $6,728 |
| Rosuvastatin Calcium | 569 | $5,215 |
| Carvedilol | 943 | $4,974 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 592 | $4,920 |
| VascepaIcosapent Ethyl | 14 | $3,679 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $301 | $268,402280 claims |
| PfizerEliquis | $281 | $263,223338 claims |
| AstraZenecaFarxiga, Brilinta | $226 | $98,938109 claims |
| Johnson & JohnsonXarelto | $248 | $84,82177 claims |
| Boehringer IngelheimJardiance | $101 | $33,89349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 acute care providers in Mississippi.
Other acute care in Oxford
- Gavin GistOxford$42K
- Sharon UptonOxford$10K
- Raquel VaughanOxford$6K
- Jene SmithOxford$3K
- Christopher BellTupelo$348K
- Kathleen ArnoldOcean Springs$217K
- Jamie DamicoOcean Springs$17K
- Dylan BoydHattiesburg$15K
- Melinda ClarkStarkville$14K
- Michelle TaylorGulfport$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.